NOVO

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
  A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks
  stat · 53m ago
• STAT+: Cancer medicines remain in short supply across the U.S., survey finds
  An ongoing shortage of cancer medications continues to force leading cancer centers around the U.S. to seek work-around strategies to treat patients and a majority also report that clinical trials…
  stat · 1h ago
• A booming business on Wall Street would love more biotechs to quietly die
  Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
  biopharma_dive · 2h ago
• Merck adds 53 to New Jersey chopping block
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 14h ago
• Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
  Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and lea…
  biospace · 1d ago
• STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
  An AstraZeneca drug reduced the dangerous flare-ups that worsen COPD in a pair of late-stage trials
  stat · 1d ago
• Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
  September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and…
  biospace · 1d ago
• STAT+: FDA names acting heads of drug and vaccine centers to permanent roles
  The moves bring stability to an agency that's been rocked by the exits of top leadership.
  stat · 1d ago
• STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals
  The FDA warned a supplier of active pharma ingredients about residue on walls, a corroded product line, and open-toed sandals at its facility. It also included photos.
  stat · 1d ago
• Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
  Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…
  endpoints · 1d ago